After encounter with antigen in animals most activated T cells die rapidly. This event relieves the animal of the burden of excess lymphocytes and reduces the risk to the animal of autoimmunity and lymphoid tumors. The death of these cells is known to involve proteins related to Bcl-2, however, the way in which these proteins interact and cause the cells to die is not known. Likewise, anergic B cells also have a shortened half life and recent experiments that this phenomenon also involves members of the Bcl-2 family. Experiments in Project 3 will investigate these problems by studying the changes in amount of, and interactions between, members of the Bcl-2 family of proteins as T cells convert from resting, long lived, to activated, rapidly dying, cells and in anergic B cells. Many of the experiments will focus on Bim, a protein which is very important in signaling lymphocytes to die, however, studies will also be performed to find out what substitutes for Bim when it is absent. In addition, viral analogs of the anti-apoptotic Bcl-2-like proteins will be studied, since one of these proteins, though active in T cells, does not seem to be able to bind Bim in the same way as Bcl-2 does. Moreover, these viral analogs act differently in T and B cells, therefore experiments on their action may reveal important differences between the ways T and B cells die. Finally, it is generally agreed that lymphocytes are actually killed by the Executioner proteins, Bak and Bax. These proteins are thought to be triggered by other pro-apoptotic proteins such as Bim. However, the means whereby Bim delivers the signal to kill to Bak and Bax is not known in spite of many years of study. This Project will follow up the idea that Bim triggers Bak and Bax via a """"""""hit and run"""""""" process, with mutational and structural studies on the Executioners and Bim.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI022295-25
Application #
8311793
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2011-08-01
Project End
2014-07-31
Budget Start
2011-08-01
Budget End
2013-07-31
Support Year
25
Fiscal Year
2011
Total Cost
$249,713
Indirect Cost
Name
National Jewish Health
Department
Type
DUNS #
076443019
City
Denver
State
CO
Country
United States
Zip Code
80206
Ruiz-Moreno, Juan Sebastian; Hamann, Lutz; Jin, Lei et al. (2018) The cGAS/STING Pathway Detects Streptococcus pneumoniae but Appears Dispensable for Antipneumococcal Defense in Mice and Humans. Infect Immun 86:
Liu, Haolin; Wang, Chao; Lee, Schuyler et al. (2018) Specific Recognition of Arginine Methylated Histone Tails by JMJD5 and JMJD7. Sci Rep 8:3275
Getahun, Andrew; Wemlinger, Scott M; Rudra, Pratyaydipta et al. (2017) Impaired B cell function during viral infections due to PTEN-mediated inhibition of the PI3K pathway. J Exp Med 214:931-941
Liu, Haolin; Wang, Chao; Lee, Schuyler et al. (2017) Clipping of arginine-methylated histone tails by JMJD5 and JMJD7. Proc Natl Acad Sci U S A 114:E7717-E7726
Rubtsova, Kira; Rubtsov, Anatoly V; Thurman, Joshua M et al. (2017) B cells expressing the transcription factor T-bet drive lupus-like autoimmunity. J Clin Invest 127:1392-1404
Lang, Julie; Ota, Takayuki; Kelly, Margot et al. (2016) Receptor editing and genetic variability in human autoreactive B cells. J Exp Med 213:93-108
Noges, Laura E; White, Janice; Cambier, John C et al. (2016) Contamination of DNase Preparations Confounds Analysis of the Role of DNA in Alum-Adjuvanted Vaccines. J Immunol 197:1221-30
Packard, Thomas A; Smith, Mia J; Conrad, Francis J et al. (2016) B Cell Receptor Affinity for Insulin Dictates Autoantigen Acquisition and B Cell Functionality in Autoimmune Diabetes. J Clin Med 5:
Morton, J Jason; Bird, Gregory; Refaeli, Yosef et al. (2016) Humanized Mouse Xenograft Models: Narrowing the Tumor-Microenvironment Gap. Cancer Res 76:6153-6158
Getahun, Andrew; Beavers, Nicole A; Larson, Sandy R et al. (2016) Continuous inhibitory signaling by both SHP-1 and SHIP-1 pathways is required to maintain unresponsiveness of anergic B cells. J Exp Med 213:751-69

Showing the most recent 10 out of 297 publications